serena williams weight loss glp 1 Is the Surprising New Face of Weight-Loss Drugs Serena Williams Shares Her GLP-1

[2] Here's what Medicare coverage for Foundayo looks like today: For weight loss: The Medicare GLP-1 Bridge (live since July 1, 2026) covers all Foundayo formulations at $50/month for eligible Part D beneficiaries (BMI-based criteria + prior authorization) Your standard Part D plan: Still excludes Foundayo for weight loss by statutethe Bridge is the pathway, not your plan's formulary No carve-out indication: Unlike Zepbound (covered under Part D for sleep apnea), Foundayo is weight-loss focusedso the $50 Bridge is essentially your only Medicare pathway Bottom line: Medicare beneficiaries now have a real weight-loss pathway for Foundayothe $50 Bridge, covering all formulations

In experiments on an AD model in rodents, GLP-1RA effectively protected cognitive abilities by improving synaptic transmission and long-term potentiation (LTP), preventing the loss of synapses and neurons

Must read up on that too

Monoaminergic Neuropathology in Alzheimer's Disease

doi: 10.1074/jbc.M110.211540 265 TomlinsonJJBoudreauAWuDAbdou SalemHCarriganAGagnonAet al

GLP-1 medicines and the treatment of obesity GLP-1RAs led to weight loss investigations, with liraglutide 3 mg daily approved for weight loss in 2014, followed by semaglutide 2.4 mg weekly in 2021, and tirzepatide in 2023